CAMBRIDGE, Mass., April 9, 2018 /PRNewswire/ -- Cancer
Treatment Centers of America® (CTCA), a national network of
comprehensive cancer care hospitals and outpatient care centers,
and Foundation Medicine, a leading molecular insights company that
recently received FDA approval for its FoundationOne CDx™ genomic
test, today announced the launch of a collaborative educational
campaign designed to heighten awareness of the promise of precision
medicine and the role that advanced genomic testing plays in
helping identify treatments best suited for individual patients.
CTCA® is an early adopter of FoundationOne CDx which became
commercially available in March, and is:
- The first and only FDA-approved broad companion diagnostic test
with Medicare coverage for qualifying patients across all solid
tumors;
- A comprehensive genomic profiling (CGP) test that helps inform
targeted and immunotherapy decisions, with insights specific to
each patient's cancer;
- A tool for physicians to identify opportunities for patients to
participate in therapeutic clinical trials; and,
- An FDA-approved platform for biopharma companies developing
precision therapeutics.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
"As our knowledge and understanding of the genetic makeup of
tumors continues to expand, so does our ability to identify more
precise treatments," said Maurie
Markman, MD, President of Medicine & Science at CTCA.
"Our partnership with Foundation Medicine and early adoption of
FoundationOne CDx reflects our corporate commitment to provide
patients with access to the latest advances in precision cancer
treatment and deliver the highest-quality care."
The collaboration brings together CTCA, a nationwide cancer care
network committed to delivering precision treatment, and Foundation
Medicine, a leader in molecular testing that offers a suite of
comprehensive genomic profiling (CGP) assays that may help identify
alterations in an individual's cancer and matches them with
potentially relevant targeted therapies, including
immunotherapies.
"Precision medicine, and the move to a more personalized,
targeted approach to cancer care, is becoming more ubiquitous
over time," said Vincent Miller, MD,
Chief Medical Officer for Foundation Medicine. "It's essential that
every stakeholder in a patient's care plan—physician, patient and
care team—is knowledgeable about the benefits of genomic profiling,
and that they can take this approach at the time of diagnosis of
advanced disease. We applaud the leadership of CTCA in this area
and we're delighted to collaborate with them on this important
educational initiative."
The campaign launched by CTCA and Foundation Medicine includes
specific patient case studies designed to educate the medical
community on how CTCA has used Foundation Medicine genomic
profiling to help inform treatment plans. The video case studies
were produced by the New York
Times' T-Brand Studio, and will be distributed through
the New York Times website and
in various digital and social media initiatives.
To learn more about genomics and precision cancer treatment,
click here or view this simple infographic. To learn more about
genomic testing and FoundationOne,
visit FoundationMedicine.com.
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information
company dedicated to a transformation in cancer care in which
treatment is informed by a deep understanding of the genomic
changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling
assays to identify the molecular alterations in a patient's cancer
and match them with relevant targeted therapies, immunotherapies
and clinical trials. Foundation Medicine's molecular information
platform aims to improve day-to-day care for patients by serving
the needs of clinicians, academic researchers and drug developers
to help advance the science of molecular medicine in cancer. For
more information, please
visit http://www.FoundationMedicine.com or
follow Foundation Medicine on Twitter
(@FoundationATCG).
About FoundationOne CDx
FoundationOne CDx is a next generation sequencing based in
vitro diagnostic device for detection of substitutions,
insertion and deletion alterations (indels), and copy number
alterations (CNAs) in 324 genes and select gene rearrangements, as
well as genomic signatures including microsatellite instability
(MSI) and tumor mutational burden (TMB) using DNA isolated from
formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.
FoundationOne CDx is intended as a companion diagnostic to identify
patients who may benefit from treatment with certain targeted
therapies in accordance with their approved therapeutic product
labeling. Additionally, FoundationOne CDx is intended to provide
tumor mutation profiling to be used by qualified health care
professionals in accordance with professional guidelines in
oncology for patients with solid malignant neoplasms. For a full
list of targeted therapies for which FoundationOne CDx is indicated
as a companion diagnostic, please
visit http://www.foundationmedicine.com/genomic-testing/foundation-one-cdx.
About Cancer Treatment Centers of America®
Cancer
Treatment Centers of America® (CTCA) is a national network of five
comprehensive cancer care hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa specializing in the
treatment of adult patients. CTCA® offers an integrative approach
that combines surgery, radiation, chemotherapy and immunotherapy
with advancements in precision cancer treatment and supportive
therapies designed to manage side effects and enhance quality of
life both during and after treatment. CTCA also offers a range of
clinical trials designed to reveal new treatments supported by
scientific and investigational research. CTCA patient satisfaction
scores consistently rank among the highest for all cancer care
providers in the country, and the hospital system is rated one of
the most admired in the U.S. in national consumer surveys. Visit
cancercenter.com, Facebook.com/cancercenter and
Twitter.com/cancercenter for more information.
CONTACT: Abigail Obre, 561
923-3198
View original
content:http://www.prnewswire.com/news-releases/cancer-treatment-centers-of-america-and-foundation-medicine-launch-joint-educational-campaign-to-raise-consumer-awareness-of-precision-medicine-approaches-in-cancer-care-300626140.html
SOURCE Cancer Treatment Centers of America